›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:AVENIO ctDNA Targeted Kit
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
RocheType:
Laboratory Developed Test
Related tests:
The AVENIO ctDNA Targeted Kit is a next-generation sequencing (NGS) liquid biopsy assay that contains 17 genes may be used for pan-cancer research applications, but is specially optimized for lung cancer and colorectal cancer (CRC). The AVENIO ctDNA Targeted Kit is an efficient tumor profiling solution. Accurate detection of all four mutation classes with high sensitivity and specificity: >99% sensitivity for SNVs, indels, CNVs, and fusions; >99% positive predictive value (PPV) for all classes of mutations.
Cancer:
Colorectal Cancer, Lung Cancer
Gene:
ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), DPYD (Dihydropyrimidine Dehydrogenase)
See More ...
ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), DPYD (Dihydropyrimidine Dehydrogenase), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MET (MET proto-oncogene, receptor tyrosine kinase), NRAS (Neuroblastoma RAS viral oncogene homolog), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), TP53 (Tumor protein P53), UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
Method:
Next-Generation Sequencing (NGS)
